MAPT and early-onset autosomal dominant Alzheimer disease: Biomarkers can aid in the clinical evaluation of Alzheimer’s disease (AD), and biomarkers currently exist for AD’s three core neuropathologies—amyloid pathology, tau pathology, and neurodegeneration [1, 2].